Literature DB >> 2874411

Mechanism of action of adjuvant chemotherapy in early breast cancer.

N Padmanabhan, A Howell, R D Rubens.   

Abstract

The relation between tumour oestrogen and progesterone receptor status, menstrual status, relapse-free survival, and overall survival was analysed in 411 patients with early breast cancer randomised to receive either postoperative adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF) or no additional treatment (control). Prolongation of time to recurrence and survival was seen predominantly in premenopausal patients; these effects were seen only with tumours positive for steroid receptors, particularly progesterone. Chemotherapy led to permanent amenorrhoea in 61% of premenopausal patients. The therapeutic effects of chemotherapy were seen only when CMF induced permanent amenorrhoea in premenopausal patients. These findings support the hypothesis that the effect of adjuvant chemotherapy in early breast cancer may be mediated by ovarian suppression.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874411     DOI: 10.1016/s0140-6736(86)92131-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  14 in total

1.  Has adjuvant treatment of breast cancer had an unfair trial?

Authors:  I Mittra
Journal:  BMJ       Date:  1990-12-08

Review 2.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

3.  Whether or not to give adjuvant chemotherapy for breast cancer.

Authors:  I E Smith
Journal:  Postgrad Med J       Date:  1988-12       Impact factor: 2.401

Review 4.  Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer.

Authors:  H C Moore
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

5.  Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients.

Authors:  Wen-Bin Zhou; Hong Yin; Xiao-An Liu; Xiao-Ming Zha; Lin Chen; Jun-Cheng Dai; Ai-di Tao; Ling Chen; Jing-Jing Ma; Li-Jun Ling; Shui Wang
Journal:  BMC Cancer       Date:  2010-06-11       Impact factor: 4.430

6.  Progesterone receptor activity and relapse-free survival in patients with primary breast cancer: the role of adjuvant chemotherapy.

Authors:  J M Raemaekers; L V Beex; G F Pieters; A G Smals; T J Benraad; P W Kloppenborg
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

7.  Host heterogeneity in female breast cancer: possible significance for pathophysiology, therapy, and prevention.

Authors:  P Cohen
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

8.  Do multiple oestrogen receptor assays give significant additional information for the management of breast cancer?

Authors:  L Castagnetta; A Traina; A Di Carlo; G Carruba; M Lo Casto; M Mesiti; R Leake
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

9.  Adjuvant tamoxifen for early breast cancer.

Authors:  I Smith
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

10.  Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.

Authors:  S Nicholson; J Richard; C Sainsbury; P Halcrow; P Kelly; B Angus; C Wright; J Henry; J R Farndon; A L Harris
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.